FDA Grants Hearing To Appeal Avastin Breast Cancer Withdrawal
Genentech and FDA will argue over revoking the accelerated approval for breast cancer before ODAC, which voted to remove the indication last July.
Genentech and FDA will argue over revoking the accelerated approval for breast cancer before ODAC, which voted to remove the indication last July.